HaemaLogiX has treated the first patient with its KMCAR T-cell therapy as part of the Phase I KOALA clinical trial for relapsed or refractory kappa-restricted multiple myeloma.
Read article +HaemaLogiX has dosed the first patient in its Phase 1 KOALA trial of KMCAR T-cell therapy, with the treatment reported as well tolerated and a second patient enrolling at a higher dose.
Read article +HaemaLogiX Ltd, a clinical-stage biotech developing novel immunotherapies for patients with blood cancers and B cell diseases, today announces a planned transition in its Board, with Dr John Cullity stepping down as Non-Executive Chair after 12 years of service. The Board has appointed co-founder Alan Liddle as incoming Non-Executive Chair.
Read article +HaemaLogiX Ltd, a clinical-stage biotech developing novel immunotherapies for patients with blood cancers and B cell diseases, is pleased to announce that it has received approval from the Human Research Ethics Committee (HREC) at the Alfred Hospital Ethics Committee (Bayside Health) for the Phase 2b clinical trial of its lead asset, KappaMab™.
Read article +